Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer

Published:2011-05 Issue:8 Volume:47 Page:1146-1151
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hawkes Eliza,Okines Alicia F.C.,Papamichael Demetris,Rao Sheela,Ashley Sue,Charalambous Haris,Koukouma Alona,Chau Ian,Cunningham David

Funder

NHS Funding

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Cancer Research, UK. http://info.cancerresearchuk.org/cancerstats/incidence/index.htm. London, UK; 2010.

2. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer;Glimelius;Ann Oncol,1997

3. Chemotherapy for advanced gastric cancer;Wagner;Cochrane Database Syst Rev,2010

4. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study);Kodera;Anticancer Res,2007

5. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy;Lee;Cancer Chemother Pharmacol,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastric transcatheter chemoembolization combined with systemic chemotherapy vs. systemic chemotherapy alone for patients with advanced gastric cardiac cancer presenting with dysphagia: A case control study;Oncology Letters;2024-06-12

2. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023;Cancer Communications;2023-12-31

3. Safety and Efficacy of of apatinib combined with chemotherapy in the second-line and subsequent lines of advanced gastric cancer: A systematic review and meta-analysis;2023-12-13

4. A Novel Online Nomogram Established with Five Features before Surgical Resection for Predicating Prognosis of Neuroblastoma Children: A Population-Based Study;Technology in Cancer Research & Treatment;2023-01

5. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study;Technology in Cancer Research & Treatment;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3